Post Traumatic Stress Disorder Market Size in the 7MM is ~USD 1,760 million in 2023, estimated DelveInsight

DelveInsight's "Post Traumatic Stress Disorder Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Post Traumatic Stress Disorder, historical and forecasted epidemiology as well as the Post Traumatic Stress Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover Key Insights into the Post Traumatic Stress Disorder Market with DelveInsight's In-Depth Report @ Post Traumatic Stress Disorder Market Size [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from Post-Traumatic Stress Disorder Market Report

* In November 2024:- Transcend Therapeutics- A Pilot Study to Assess the Use of Methylone in the Treatment of PTSD IMPACT-1 (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD]). Eligible participants will enter a 4-week Treatment Period where they will receive methylone once weekly for 4 weeks (4 treatment sessions). Following the Treatment Period, participants will enter a 6-week Follow-up Period which includes 3 reflection visits (Week 4, 5, and 6) and a final study visit at Week 10.
* In November 2024, Silo Pharma has secured an exclusive license agreement with Medspray Pharma BV for intranasal technology utilized in the SPC-15 treatment targeting PTSD.
* In September 2023, The US FDA reported favorable initial findings from its Phase IIb ATTUNE trial evaluating BNC210 for PTSD treatment.
* In the 7MM, the total 12-month prevalent cases of PTSD were around 13.8 Million in 2023 and are projected to increase during the forecasted period.
* Among EU4 countries, France accounted for the largest number of Post-traumatic Stress Disorder cases, followed by Germany, whereas Italy accounted for the lowest number of cases in 2022.
* According to DelveInsight estimates, in Japan, the total severity-specific cases of Post-traumatic Stress Disorder were 489,000, 44,000, and 212,150 in mild, moderate, and severe, respectively, in 2023. These cases are projected to increase during the forecast period.
* The leading Post Traumatic Stress Disorder Companies such as Nobilis Therapeutics, Otsuka Pharma, Compass Pathways, Aptinyx, Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, GlaxoSmithKline, KGK Science Inc., AstraZeneca, UCB Pharma, Bionorica SE, Bionomics Limited, Pfizer, and others
* Promising Post Traumatic Stress Disorder Therapies such as REXULTI plus-minus ZOLOFT, NBTX001, Brexpiprazole, COMP360, NYX-783, JZP150, Psilocybin, BNC210, BI 1358894, orvepitant, Psilocybin, Quetiapine Fumarate, levetiracetam, BX-1, BNC210, Ziprasidone, and others

Stay ahead in the Post Traumatic Stress Disorder Therapeutics Market with DelveInsight's Strategic Report @ Post Traumatic Stress Disorder Market Outlook [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Post Traumatic Stress Disorder Epidemiology

* Total Prevalence of Post Traumatic Stress Disorder
* Prevalent Cases of Post Traumatic Stress Disorder by severity
* Gender-specific Prevalence of Post Traumatic Stress Disorder
* Diagnosed Cases of Episodic and Chronic Post Traumatic Stress Disorder

Download the report to understand which factors are driving Post Traumatic Stress Disorder epidemiology trends @ Post Traumatic Stress Disorder Prevalence [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Post Traumatic Stress Disorder Emerging Drugs

* Brexpiprazole + Sertraline: Otsuka Pharmaceuticals

Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, nor-adrenergic alpha 1B and 2C receptors. ZOLOFT is an antidepressant that belongs to a group of drugs called selective serotonin reuptake inhibitors (SSRIs). It affects chemicals in the brain that may be unbalanced in people with depression, panic, anxiety, or obsessive-compulsive symptoms.

* BNC210: Bionomics

BNC210 is Bionomics's proprietary molecule in development for the treatment of Social Anxiety Disorder (SAD), post-traumatic stress disorder, and anxiety disorders as a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor (7 nAChR). It has a novel mechanism of action, and extensive non-clinical and clinical studies have shown it has several properties that may be useful to treat post-traumatic stress disorder, SAD, and anxiety disorders. The drug is being evaluated in Phase IIb (NCT04951076, ATTUNE) in adults with post-traumatic stress disorder. The study is completed by May 2023.

Post-traumatic Stress Disorder Market Outlook

The pharmaceutical market for post-traumatic stress disorder is focused on developing treatments that can alleviate the symptoms of this condition. The FDA has approved only two drugs, ZOLOFT (sertraline) and PAXIL (paroxetine), for treating post-traumatic stress disorder. These drugs are primarily used to alleviate symptoms rather than cure them; however, their patents have expired, and several generics are available. The current market has been segmented into different commonly used drugs based on the prevailing treatment pattern across the 7MM, presenting minor variations in the overall prescription pattern. Antidepressants, antipsychotics, benzodiazepines, and other drugs are covered in the forecast model.

Get In-Depth Knowledge on Post Traumatic Stress Disorder Market Trends and Forecasts with DelveInsight @ Post Traumatic Stress Disorder Treatment Market [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Post Traumatic Stress Disorder Therapies and Companies

* REXULTI plus-minus ZOLOFT: Otsuka Pharmaceutical
* NBTX001: Nobilis Therapeutics
* Brexpiprazole: Otsuka Pharma
* COMP360: Compass Pathways
* NYX-783: Aptinyx
* JZP150: Jazz Pharmaceuticals
* Psilocybin: COMPASS Pathways
* BNC210: Bionomics Limited
* BI 1358894: Boehringer Ingelheim
* orvepitant: GlaxoSmithKline
* Psilocybin: KGK Science Inc.
* Quetiapine Fumarate: AstraZeneca
* levetiracetam: UCB Pharma
* BX-1: Bionorica SE
* Ziprasidone: Pfizer

Post Traumatic Stress Disorder Therapeutics Market

New diagnostic categories modeled on PTSD have been proposed, including prolonged duress stress disorder, post-traumatic grief disorder, post-traumatic relationship syndrome, post-traumatic dental care anxiety, and post-traumatic abortion syndrome. The introduction of novel drugs and the class of new therapeutic drugs to treat PTSD in the market will bring hope to the PTSD patients as a therapeutic option and might have a major positive effect on the market.

Scope of the Post Traumatic Stress Disorder Market Report

* Study Period: 2020-2034
* Coverage: 7MM
* Post Traumatic Stress Disorder Companies: Nobilis Therapeutics, Otsuka Pharma, Compass Pathways, Aptinyx, Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, GlaxoSmithKline, KGK Science Inc., AstraZeneca, UCB Pharma, Bionorica SE, Bionomics Limited, Pfizer, and others
* Post Traumatic Stress Disorder Therapies: REXULTI plus-minus ZOLOFT, NBTX001, Brexpiprazole, COMP360, NYX-783, JZP150, Psilocybin, BNC210, BI 1358894, orvepitant, Psilocybin, Quetiapine Fumarate, levetiracetam, BX-1, BNC210, Ziprasidone, and others
* Post Traumatic Stress Disorder Therapeutic Assessment: Post Traumatic Stress Disorder current marketed and Post Traumatic Stress Disorder emerging therapies
* Post Traumatic Stress Disorder Market Dynamics: Post Traumatic Stress Disorder market drivers and Post Traumatic Stress Disorder market barriers

Unlock Strategic Insights with DelveInsight's Comprehensive Post Traumatic Stress Disorder Market Report @ Post Traumatic Stress Disorder Market Drivers and Barriers [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

1. Post Traumatic Stress Disorder Market Report Introduction

2. Executive Summary for Post Traumatic Stress Disorder

3. SWOT analysis of Post Traumatic Stress Disorder

4. Post Traumatic Stress Disorder Patient Share (%) Overview at a Glance

5. Post Traumatic Stress Disorder Market Overview at a Glance

6. Post Traumatic Stress Disorder Disease Background and Overview

7. Post Traumatic Stress Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Post Traumatic Stress Disorder

9. Post Traumatic Stress Disorder Current Treatment and Medical Practices

10. Post Traumatic Stress Disorder Unmet Needs

11. Post Traumatic Stress Disorder Emerging Therapies

12. Post Traumatic Stress Disorder Market Outlook

13. Country-Wise Post Traumatic Stress Disorder Market Analysis (2020-2034)

14. Post Traumatic Stress Disorder Market Access and Reimbursement of Therapies

15. Post Traumatic Stress Disorder Market Drivers

16. Post Traumatic Stress Disorder Market Barriers

17. Post Traumatic Stress Disorder Appendix

18. Post Traumatic Stress Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=post-traumatic-stress-disorder-market-size-in-the-7mm-is-usd-1760-million-in-2023-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.